Profile data is unavailable for this security.
About the company
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
- Revenue in USD (TTM)17.16m
- Net income in USD-163.62m
- Incorporated2005
- Employees117.00
- LocationAnaptysBio Inc10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 362-6295
- Fax+1 (858) 362-6296
- Websitehttps://www.anaptysbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp | 18.14m | -72.85m | 495.48m | 73.00 | -- | 4.41 | -- | 27.31 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -62.74m | 500.00m | 129.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -6.83 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -3.73 | -- | -- | -- |
| Altimmune Inc | 426.00k | -88.45m | 501.94m | 59.00 | -- | 2.58 | -- | 1,178.26 | -1.64 | -1.64 | 0.008 | 2.75 | 0.002 | -- | 0.6636 | 7,220.34 | -42.36 | -39.62 | -45.55 | -42.58 | -- | -- | -20,762.21 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Alector Inc | 97.06m | -130.39m | 502.68m | 244.00 | -- | 3.32 | -- | 5.18 | -1.56 | -1.56 | 1.16 | 1.58 | 0.1377 | -- | 75.04 | 397,795.10 | -18.50 | -20.00 | -22.92 | -23.81 | -- | -- | -134.34 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Nkarta Inc | 0.00 | -117.50m | 503.27m | 150.00 | -- | 1.29 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Phibro Animal Health Corp | 982.01m | 14.80m | 508.73m | 1.92k | 34.38 | 1.88 | 10.25 | 0.518 | 0.3654 | 0.3654 | 24.24 | 6.69 | 1.02 | 2.37 | 6.49 | 511,465.60 | 1.53 | 5.46 | 1.87 | 6.83 | 30.43 | 31.41 | 1.51 | 5.11 | 1.60 | 2.50 | 0.6369 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Absci Corp | 5.72m | -110.57m | 510.91m | 155.00 | -- | 2.39 | -- | 89.35 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -69.33m | 512.45m | 40.00 | -- | -- | -- | -- | -2.17 | -2.17 | 0.00 | 4.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| AnaptysBio Inc | 17.16m | -163.62m | 515.72m | 117.00 | -- | 5.82 | -- | 30.06 | -6.07 | -6.07 | 0.6372 | 3.31 | 0.0323 | -- | 4.15 | 146,641.00 | -30.79 | -18.08 | -32.75 | -18.96 | -- | -- | -953.66 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Celcuity Inc | 0.00 | -63.78m | 515.88m | 55.00 | -- | 3.09 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 519.00m | 232.00 | -- | 1.00 | -- | 5,463.14 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Exscientia PLC (ADR) | 25.02m | -181.89m | 520.87m | 483.00 | -- | 1.17 | -- | 20.82 | -1.45 | -1.45 | 0.199 | 3.53 | 0.0346 | 1,096.08 | 9.86 | 51,802.40 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| SNDL Inc | 663.51m | -122.72m | 520.98m | 2.52k | -- | 0.594 | -- | 0.7852 | -0.4711 | -0.4838 | 2.56 | 3.37 | 0.5995 | 5.29 | 36.58 | 263,715.40 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 533.74m | 452.00 | -- | -- | -- | 782.61 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
| OmniAB Inc | 34.16m | -50.62m | 534.09m | 106.00 | -- | 1.69 | -- | 15.63 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to AnaptysBio Inc's reporting currency: US Dollar USD
72.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Dec 2023 | 7.52m | 28.10% |
| Deep Track Capital LPas of 31 Dec 2023 | 2.04m | 7.61% |
| Tang Capital Management LLCas of 31 Dec 2023 | 1.95m | 7.29% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.56m | 5.84% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.33m | 4.99% |
| First Light Asset Management LLCas of 31 Dec 2023 | 1.24m | 4.62% |
| Woodline Partners LPas of 31 Dec 2023 | 1.19m | 4.47% |
| Great Point Partners LLCas of 31 Dec 2023 | 976.98k | 3.65% |
| Point72 Asset Management LPas of 31 Dec 2023 | 788.55k | 2.95% |
| Palo Alto Investors LPas of 31 Dec 2023 | 686.88k | 2.57% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
